![](/images/graphics-bg.png)
Patients with Multiple Myeloma Develop SOX2-Specific Autoantibodies after Allogeneic Stem Cell Transplantation
Joint Authors
Haag, Friedrich
Kobold, Sebastian
Atanackovic, Djordje
Marx, Andreas
Templin, Julia
Hildebrandt, York
Tams, Sinje
Sezer, Orhan
Reinhard, Henrike
Bokemeyer, Carsten
Bartels, Britta Marlen
Kröger, Nicolaus
Luetkens, Tim
Lajmi, Nesrine
Bartels, Katrin
Cao, Yanran
Source
Journal of Immunology Research
Issue
Vol. 2011, Issue 2011 (31 Dec. 2010), pp.1-10, 10 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2011-11-15
Country of Publication
Egypt
No. of Pages
10
Main Subjects
Abstract EN
The occurrence of SOX2-specific autoantibodies seems to be associated with an improved prognosis in patients with monoclonal gammopathy of undetermined significance (MGUS).
However, it is unclear if SOX2-specific antibodies also develop in established multiple myeloma (MM).
Screening 1094 peripheral blood (PB) sera from 196 MM patients and 100 PB sera from healthy donors, we detected SOX2-specific autoantibodies in 7.7% and 2.0% of patients and donors, respectively.
We identified SOX2211–230 as an immunodominant antibody-epitope within the full protein sequence.
SOX2 antigen was expressed in most healthy tissues and its expression did not correlate with the number of BM-resident plasma cells.
Accordingly, anti-SOX2 immunity was not related to SOX2 expression levels or tumor burden in the patients’ BM.
The only clinical factor predicting the development of anti-SOX2 immunity was application of allogeneic stem cell transplantation (alloSCT).
Anti-SOX2 antibodies occurred more frequently in patients who had received alloSCT (n=74).
Moreover, most SOX2-seropositive patients had only developed antibodies after alloSCT.
This finding indicates that alloSCT is able to break tolerance towards this commonly expressed antigen.
The questions whether SOX2-specific autoantibodies merely represent an epiphenomenon, are related to graft-versus-host effects or participate in the immune control of myeloma needs to be answered in prospective studies.
American Psychological Association (APA)
Kobold, Sebastian& Tams, Sinje& Luetkens, Tim& Cao, Yanran& Sezer, Orhan& Bartels, Britta Marlen…[et al.]. 2011. Patients with Multiple Myeloma Develop SOX2-Specific Autoantibodies after Allogeneic Stem Cell Transplantation. Journal of Immunology Research،Vol. 2011, no. 2011, pp.1-10.
https://search.emarefa.net/detail/BIM-1027699
Modern Language Association (MLA)
Kobold, Sebastian…[et al.]. Patients with Multiple Myeloma Develop SOX2-Specific Autoantibodies after Allogeneic Stem Cell Transplantation. Journal of Immunology Research Vol. 2011, no. 2011 (2010), pp.1-10.
https://search.emarefa.net/detail/BIM-1027699
American Medical Association (AMA)
Kobold, Sebastian& Tams, Sinje& Luetkens, Tim& Cao, Yanran& Sezer, Orhan& Bartels, Britta Marlen…[et al.]. Patients with Multiple Myeloma Develop SOX2-Specific Autoantibodies after Allogeneic Stem Cell Transplantation. Journal of Immunology Research. 2011. Vol. 2011, no. 2011, pp.1-10.
https://search.emarefa.net/detail/BIM-1027699
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1027699